Sponsored by
A promising new combination approach from ImmunityBio, Inc. is gaining attention after one patient helped reveal its potential for recurrent glioblastoma (GBM). An initial study tested natural killer (NK)-cell immunotherapy combined with Anktiva, an engineered IL-15 agonist, plus bevacizumab; the trial allowed participants to use Optune but didn’t require it. However, when the first patient wearing Optune enrolled and did well on treatment, his unusually strong response suggested that the device may enhance how NK cells and Anktiva work together against GBM. These results prompted the launch of a further Phase 2b portion of the trial to see if the benefit can be replicated. This story highlights an important point that GBM immunotherapy trials should make an effort to include patients who want to use Optune.